



COMMONWEALTH OF KENTUCKY  
OFFICE OF THE GOVERNOR

Andy Beshear  
GOVERNOR

Capitol Building, Suite 100  
700 Capitol Avenue  
Frankfort, KY 40601  
(502) 564-2611  
Fax: (502) 564-2517

June 27, 2025

Hon. Russell Coleman  
Attorney General  
Commonwealth of Kentucky  
700 Capital Avenue, Suite 118  
Frankfort, Kentucky 40601

Dear General Coleman:

We are in receipt of your letter dated June 17, 2025 about the issuance of a death warrant and setting an execution date for Ralph Baze. As an initial matter, please send to my office for review a copy of the complete file the Office of the Attorney General possesses on Ralph Baze and any additional information you believe I should review.

My understanding is that there are several steps that must occur through the Department of Corrections (DOC) before the execution of any death warrant. Specifically, the Franklin Circuit Court has ruled that further changes must be made to 501 KAR 16:310 because it currently limits the evaluation of an inmate's intellectual disability solely to that person's prison medical records. *Baze v. KDOC*, 06-CI-00574 (Franklin Cir. Ct. Apr. 24, 2025). In accordance with the Franklin Circuit Court's April 24, 2025 ruling, DOC is taking steps to amend 501 KAR 16:310 to allow for the review of records outside a condemned inmate's prison medical records. To that end, DOC is working with the Kentucky Department of Public Advocacy to determine the scope of records that should be considered under 501 KAR 16:310 and is committed to publishing an amended regulation for comment by July 15, 2025.

In addition, DOC does not currently possess the drugs necessary to perform a lethal injection. The shelf life of those drugs is limited and precludes DOC from seeking them until the injunction is lifted. Further, since 2018, DOC has received notifications from three different companies that they are unwilling to provide drugs for their use in executions. We attach these notifications for your review.

Sincerely,

A handwritten signature in blue ink that reads "Andy Beshear".

Andy Beshear  
Governor

Meitheal Pharmaceuticals  
8700 W. Bryn Mawr, Suite 600S  
Chicago, IL 60631



March 21, 2025

*(Sent via USPS First Class Mail)*

Leah Boggs  
Acting GC and Executive Director  
Justice & Public Safety Cabinet  
125 Holmes Street  
Frankfort, KY 40601

Dear Ms. Boggs:

I write on behalf of Meitheal Pharmaceuticals, Inc. ("Meitheal") regarding Meitheal's position on the use of our products in lethal injection protocols and the steps we have taken to protect our products from being used for this purpose.

It is our understanding that Cisatracurium Besylate and Rocuronium Bromide, among other products, are currently being sought or may be sought in the future by the Kentucky Department of Corrections for use in lethal injection executions. The use of Cisatracurium Besylate and Rocuronium Bromide or any other product sold by Meitheal in lethal injection executions is not only inconsistent with, but is wholly contradictory to, the FDA-approved indications for such products.

While Meitheal takes no position on the death penalty itself, Meitheal objects to the use of its products in capital punishment. At Meitheal, we strive to develop products used to save and improve patients' lives. The use of Meitheal's products to conduct executions is fundamentally inconsistent with this mission.

In alignment with industry standards, and to prevent Cisatracurium Besylate, Rocuronium Bromide, or any other product sold by Meitheal from being used outside of FDA-approved indications, Meitheal has imposed a system of strict distribution controls designed to prohibit the direct or indirect sale of its products to correctional facilities for use in lethal injections. Specifically, Meitheal's written agreements with its distributors stipulate that the products in question are not to be sold to any correctional entity for any reason without specific approval from Meitheal.

Moreover, Meitheal is committed to adhering to regulations that promote transparency within the pharmaceutical supply chain to protect public health. In line with this goal, and to protect the quality and integrity of our drugs, Meitheal strongly opposes any efforts to subvert our distribution controls or to seek to conceal the supply chain for drugs acquired for use in capital punishment. If Meitheal's products are diverted from legitimate channels in violation of our distribution controls, they risk being counterfeit, stolen, contaminated, or otherwise harmful.

If Meitheal must implement additional controls to prevent the misuse of its products in response to attempts to divert its products, those actions may have the unintended consequence of preventing patients in genuine medical need from receiving medication. This outcome would not be good for anyone, particularly the good people of Kentucky. As such, we hope that you will be our partner in upholding our policy prohibiting Meitheal's products from being used for capital punishment.

If you have any questions or would like to discuss these issues further, please do not hesitate to contact me.

Sincerely,

Victoria A. Wohlfeil  
General Counsel & Corporate Secretary  
Meitheal Pharmaceuticals, Inc.

State Governor  
State Attorney General  
Director of the State Department of Corrections

April 20, 2018

Dear Warden White,

My name is Andrea Sweet and I am a Vice President, Legal Affairs at Alvogen, Inc.

Alvogen is aware that certain medicines we manufacture for specific healthcare applications are currently sought by some correctional facilities in the US for use in lethal injection executions.

I am writing to communicate in the clearest possible terms that Alvogen strongly objects to the use of its products in capital punishment. While Alvogen takes no position on the death penalty itself, our products were developed to save and improve patients' lives and their use in executions is fundamentally contrary to this purpose.

To ensure our products are not purchased for use in lethal injection executions, Alvogen does not accept orders from any state departments of corrections. Further, Alvogen has controls in place and directs its customers not to sell its medicines to correctional facilities or otherwise for use in connection with lethal injection executions. These controls reflect our company's policy of ensuring the appropriate use of our medicines.

The use of Alvogen products, such as midazolam or rocuronium, in executions clearly runs counter to the FDA-approved indication for these products. If your state has purchased products manufactured by Alvogen for use in capital punishment procedures – either directly or indirectly – we ask that you immediately return our products in exchange for a full refund.

Finally, I have been informed that some states have implemented "secrecy policies/laws" which they hope will enable them to bypass company control systems and purchase manufactured medicines for use in executions. Alvogen closely tracks the distribution of its medicines as required by law and will take action in case of such diversions. Transparency across the supply chain is important to protect public health and the commercial interests of healthcare companies.

If you require further clarification regarding our opposition to the misuse of medicines in executions or have questions about specific products you have purchased from Alvogen, please do not hesitate to contact me; I would be glad to discuss these issues further.

Sincerely,



Andrea Sweet  
Vice President, Legal Affairs



FILE  
SS

18 July 2022

Mr. Scott Jordan, Warden  
Kentucky State Penitentiary  
266 Water Street  
Eddyville, KY 42038

**Re: Piramal's Opposition to the Misuse of Our Products in Capital Punishment Procedures**

This letter on behalf of Piramal Pharma Limited (collectively with its affiliates, "Piramal") is to express our position, and strong objection, in connection with the use of Piramal manufactured, marketed and/or distributed products in connection with capital punishments procedures. Piramal has a long-standing opposition to the misuse of our medicinal products and intends that all of our products are used only for the indications for which they are approved.

Piramal's mission statement is saving and improving patient lives. While Piramal takes no position on the death penalty itself, our products are used to alleviate the pain and suffering of patients, and any use of our products in capital punishment procedures is fundamentally contrary to this purpose. Piramal respectfully requests that State officials not seek to purchase Piramal products for use in connection with capital punishment procedures and to the extent that State officials can procure Piramal products, we request that these not be used directly or indirectly in capital punishment procedures. State correctional health facilities wishing to purchase such restricted medicine products for use in genuine patient care in accordance with approved indications may do so if they provide an affidavit stating under penalty of perjury that the products will not be used directly or indirectly in capital punishment procedures.

To the extent that the State has previously purchased and still has on hand any Piramal products intended by the State for use in capital punishment procedures, including lethal injection executions, we request that you immediately arrange to destroy the products or contact the wholesaler or distributor where you purchased such product to coordinate a return in exchange for a full refund.

If you require further clarification regarding our opposition to the misuse of medicines in capital punishment procedures or have questions about specific products you may have purchased from Piramal, please do not hesitate to contact me.

Sincerely,

A handwritten signature in blue ink, appearing to read "Ahmad T. Aboelezz", with a long horizontal flourish extending to the right.

Ahmad T. Aboelezz, Esq.  
Head of Legal, Global Pharma  
Piramal Critical Care | Piramal Pharma Solutions  
(610) 810-4554  
[ahmad.aboelezz@piramal.com](mailto:ahmad.aboelezz@piramal.com)  
[piramalcriticalcare.com](http://piramalcriticalcare.com)  
[piramalpharmasolutions.com](http://piramalpharmasolutions.com)



**Piramal's Position on Use of Our Products in Lethal Injections  
for Capital Punishment**

Piramal Pharma Limited is a values driven organization with a purpose of "Doing Well and Doing Good." We stay true to our purpose by serving others, making a positive difference, and living our core values.

Piramal Pharma Limited is comprised of Piramal Pharma Solutions, Piramal Critical Care and the Consumer Products Division. Piramal Pharma serves patients by making and supplying products that help enhance and save lives, and we do not support or condone the use of any of the products we make or supply in any way that is inconsistent with the approved indications and labeling of such products, including any use in connection with capital punishment.